A Phase 1 interventional study of Bimagrumab and Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of bimagrumab subcutaneously (SC)
Drug: Bimagrumab
Participants will receive a single dose of bimagrumab SC and a single dose of tirzepatide SC
Drug: Bimagrumab · Drug: Tirzepatide
Participants will receive a single dose of bimagrumab with tirzepatide SC
Drug: Bimagrumab + Tirzepatide Coformulation
Participants will receive bimagrumab SC and tirzepatide SC for 4 weeks
Drug: Bimagrumab · Drug: Tirzepatide
Participants will receive bimagrumab with tirzepatide SC for 4 weeks
Drug: Bimagrumab + Tirzepatide Coformulation
Administered SC
Also known as: LY3985863, BYM338, VER201
Administered SC
Also known as: LY3298176
Administered SC
Also known as: LY900042
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material
Time frame: Predose through Week 13
PK: Cmax of Bimagrumab Reference Material
Time frame: Predose through Week 13
PK: Cmax of Bimagrumab Coadministered with Tirzepatide
Time frame: Predose through Week 13
PK: Cmax of Tirzepatide Coadministered with Bimagrumab
Time frame: Predose through Week 16
PK: Cmax of Bimagrumab Coformulated with Tirzepatide
Time frame: Predose through Week 16
PK: Cmax of Tirzepatide Coformulated with Bimagrumab
Time frame: Predose through Week 16
PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test Material
Time frame: Predose through Week 13
PK: AUC(0-∞) of Bimagrumab Reference Material
Time frame: Predose through Week 13
PK: AUC(0-∞) of Bimagrumab Coadministered with Tirzepatide
Time frame: Predose through Week 13
PK: AUC(0-∞) of Tirzepatide Coadministered with Bimagrumab
Time frame: Predose through Week 16
PK: AUC(0-∞) of Bimagrumab Coformulated with Tirzepatide
Time frame: Predose through Week 16
PK: AUC(0-∞) of Tirzepatide Coformulated with Bimagrumab
Time frame: Predose through Week 16
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Sep 2025, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab